Shaping the Future of Nephrology at WCN 2025
Fresenius Medical Care is proud to sponsor WCN 2025, advancing nephrology through improved quality standards and the transition at HDF. As a trusted partner, we're committed to driving innovation in research and patient care. Here are the event highlights:
Real Stories, Real Impact:
Hear directly from patients who have experienced the benefits of HDF firsthand. Learn about the positive outcomes and real-life impacts of this therapy in their lives.
Discover how this therapy has improved their lives through positive outcomes and meaningful real-world impacts.
Join Us on Friday, February 7th at WCN 2025
Hear from leading nephrologists from India and around the world, with a special presentation by a patient currently benefiting from HDF therapy. Don't miss these insightful perspectives on the future of nephrology and a pragmatic approach on how to implement HDF in your clinic.
Benefits of HighVolumeHDF:
- 23% risk reduction of mortality vs. HD (CONVINCE Study, 2023).1
- 28% risk reduction in hypotension episodes (ESHOL Study, 2013).2
- Improved patient quality of life: better results in cognitive, physical and social functions, and less pain interference (CONVINCE Study, 2024).3
- Up to 9% reduction in EPO use for HDF compared to HD use (NICE RRT Guidelines, 2018).4
- Up to 28% savings in dialysis fluid with AutoFlow (5008 series & 6008 CAREsystem)*.
*based on internal calculations
Want to know more? Visit our Booth B13 at WCN 2025!
Discover the full benefits of HighVolumeHDF and speak with our experts.
Get in touch with us
- Blankenstijn PJ et al. CONVINCE Scientific Committee Investigators, Effect of Hemodiafiltration or Hemodialysis on Mortality in Kidney Failure N Engl J Med. 2023;389(8):700-709.
- Maduell F. et al., High-Efficiency Postdilution Online Hemodiafiltration Reduces All-Cause Mortality in Hemodialysis Patients. J Am Soc Nephrol (2013); 24: 487-497.
- Rose M et al., The CONVINCE randomized trial found positive effects on quality of life for patients with chronic kidney disease treated with hemodiafiltration, Kidney Int 2024 Nov;106(5):961-971.
- www.nice.org.uk/guidance/ng107, Renal replacement therapy and conservative management, published date: October 2018.
* All statements and assessments by NICE are based on care practice and costs in England.
©Fresenius Medical Care Deutschland GmbH